A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
LIFECORE BIOMEDICAL, INC. \DE\
LFCR
$151M
Mkt Cap
$4.33
-2.26%
LIFECORE BIOMEDICAL, INC. \DE\ (LFCR) has a 5-year average return on invested capital (ROIC) of -16.4%. This is below average and may indicate limited pricing power.
LIFECORE BIOMEDICAL, INC. \DE\ (LFCR) has a market capitalization of $162M. It is classified as a small-cap stock.
LIFECORE BIOMEDICAL, INC. \DE\ (LFCR) does not currently pay a regular dividend.
LIFECORE BIOMEDICAL, INC. \DE\ (LFCR) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
LIFECORE BIOMEDICAL, INC. \DE\ (LFCR) reported annual revenue of $129 million in its most recent fiscal year, based on SEC EDGAR filings.
LIFECORE BIOMEDICAL, INC. \DE\ (LFCR) has a net profit margin of -34.4%. The company is currently unprofitable.
LIFECORE BIOMEDICAL, INC. \DE\ (LFCR) generated $-14 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
The Company Lifecore Biomedical, Inc. and its subsidiaries (“Lifecore”, the “Company”, “we” or “us”), located in Chaska, Minnesota, is a fully integrated contract development and manufacturing organization (“CDMO”) that offers highly differentiated clinical and commercial capabilities in the development, cGMP manufacturing and aseptic filling of complex formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials and cartridges, across a wide variety of modalities. Lifecore has become a leading U.S. manufacturer of pharmaceutical-grade, non-animal-sourced hyaluronic acid (“HA”) using our proprietary, fermentation-based HA process that we developed in 1981. We manufacture HA in bulk form as well as for use in formulated and filled syringes and vials for our customers’ injectable products used in treating a broad spectrum of medical conditions and procedures, including ophthalmic and orthopedic applications.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 134M | 129M | 128M | 103M | 111M | 101M |
| Net Income | -41M | -44M | 12M | -100M | -117M | -32M |
| EPS | $-1.11 | $-1.27 | $0.33 | $-3.32 | $-3.97 | $-1.10 |
| Free Cash Flow | -956K | -14M | -18M | -39M | -53M | -8.8M |
| ROIC | -9.6% | -36.2% | 10.7% | -50.7% | -3.4% | -2.2% |
| Gross Margin | 29.5% | 31.3% | 32.6% | 27.1% | 35.1% | 38.6% |
| Debt/Equity | 0.00 | 93.29 | 8.98 | -20.19 | 3.46 | 0.97 |
| Dividends/Share | $0.00 | - | - | $0.01 | - | - |
| Operating Income | -9.8M | -17M | -8.8M | -22M | -12M | -8.8M |
| Operating Margin | -7.4% | -13.4% | -6.9% | -21.1% | -10.6% | -8.7% |
| ROE | 0.0% | -701.3% | 106.2% | - | -85.5% | -16.0% |
| Shares Outstanding | 37M | 35M | 36M | 30M | 29M | 29M |
| Metric | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||
| Revenue | 477M | 539M | 477M | 470M | 524M | 558M | 590M | 101M | 111M | 103M | 128M | 129M | 134M |
| Gross Margin | 13.1% | 12.1% | 14.0% | 16.9% | 14.9% | 14.5% | 12.7% | 38.6% | 35.1% | 27.1% | 32.6% | 31.3% | 29.5% |
| R&D | 7.2M | 7.0M | 7.2M | 9.5M | 13M | 11M | 11M | 6.7M | 7.8M | 8.7M | 8.6M | 8.3M | 8.1M |
| SG&A | 35M | 40M | 46M | 52M | 52M | 62M | 72M | 28M | 35M | 39M | 40M | 44M | 36M |
| EBIT | 20M | 18M | -21M | 15M | 14M | 5.5M | -39M | -8.8M | -12M | -22M | -8.8M | -17M | -9.8M |
| Op. Margin | 4.2% | 3.4% | -4.3% | 3.1% | 2.6% | 1.0% | -6.5% | -8.7% | -10.6% | -21.1% | -6.9% | -13.4% | -7.4% |
| Net Income | 19M | 14M | -12M | 11M | 25M | 411K | -38M | -32M | -117M | -100M | 12M | -44M | -41M |
| Net Margin | 4.0% | 2.5% | -2.4% | 2.3% | 4.7% | 0.1% | -6.5% | -32.0% | -104.9% | -96.4% | 9.4% | -34.4% | -30.8% |
| Non-Recurring | -329K | 90K | -46K | -586K | -157K | -188K | 25M | 13M | 28M | -12M | 2.5M | -5.2M | -5.2M |
| Returns on Capital | |||||||||||||
| ROIC | 6.2% | 5.1% | -4.6% | 4.1% | 4.9% | 1.0% | -11.5% | -2.2% | -3.4% | -50.7% | 10.7% | -36.2% | -9.6% |
| ROE | 10.0% | 6.4% | -5.4% | 4.8% | 10.4% | 0.2% | -16.5% | -16.0% | -85.5% | N/A | 106.2% | -701.3% | 0.0% |
| ROA | 6.3% | 4.1% | -3.4% | 3.0% | 6.5% | 0.1% | -7.1% | -6.4% | -30.0% | -39.3% | 4.7% | -18.0% | -17.5% |
| Cash Flow | |||||||||||||
| Op. Cash Flow | 21M | 27M | 21M | 30M | 20M | 16M | -17M | 16M | -23M | -17M | 257K | -206K | 10M |
| Free Cash Flow | 6.2M | 9.1M | -19M | 6.8M | -14M | -29M | -44M | -8.8M | -53M | -39M | -18M | -14M | -956K |
| Owner Earnings | 13M | 18M | 7.9M | 15M | 3.0M | -2.8M | -38M | -6.8M | -43M | -34M | -14M | -18M | -7.0M |
| CapEx | 15M | 18M | 40M | 23M | 34M | 45M | 27M | 25M | 30M | 21M | 18M | 13M | 11M |
| Maint. CapEx | 7.1M | 7.1M | 9.4M | 11M | 12M | 15M | 19M | 20M | 18M | 13M | 8.0M | 8.0M | 8.0M |
| Growth CapEx | 7.8M | 10M | 30M | 12M | 21M | 30M | 7.8M | 5.4M | 12M | 8.3M | 10M | 5.4M | 3.1M |
| D&A | 7.1M | 7.1M | 9.4M | 11M | 12M | 15M | 19M | 20M | 18M | 13M | 8.0M | 8.0M | 8.0M |
| CapEx/OCF | N/A | N/A | N/A | 77.4% | 169.8% | 279.2% | N/A | 153.1% | N/A | N/A | 7157.6% | N/A | 109.5% |
| Capital Allocation | |||||||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 343K | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.1% | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | 0.0% | 0.0% | 0.0% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 1.4M | 1.6M | 3.5M | 4.0M | 4.4M | 3.6M | 2.4M | 3.4M | 2.6M | 3.6M | 6.2M | 10M | 9.2M |
| Debt Repayment | 5.9M | 6.9M | 15M | 57M | 5.1M | 5.1M | 11M | 114M | 86M | 124M | 231K | 435K | 435K |
| Balance Sheet | |||||||||||||
| Net Debt | 20M | 28M | 44M | 41M | 39M | 96M | 190M | 193M | 234M | 47M | 85M | 108M | 92M |
| Cash & Equiv. | 14M | 14M | 10.0M | 6.0M | 2.9M | 1.1M | 360K | 763K | 5.9M | 19M | 8.5M | 8.3M | 38M |
| Long-Term Debt | 28M | 34M | 46M | 42M | 37M | 87M | 101M | 165M | 99M | 84M | 101M | 121M | 129M |
| Debt/Equity | 0.17 | 0.19 | 0.26 | 0.21 | 0.17 | 0.36 | 0.82 | 0.97 | 3.46 | -20.19 | 8.98 | 93.29 | 0.00 |
| Interest Coverage | 12.2 | 10.1 | -10.4 | 56.2 | 67.9 | 10.6 | -4.0 | -1.0 | -0.8 | -0.9 | N/A | -0.8 | -0.8 |
| Equity | 203M | 218M | 211M | 227M | 253M | 270M | 231M | 202M | 71M | -4.2M | 11M | 1.3M | -11M |
| Total Assets | 314M | 346M | 343M | 359M | 405M | 519M | 541M | 502M | 276M | 254M | 254M | 239M | 235M |
| Total Liabilities | 109M | 126M | 130M | 130M | 152M | 249M | 310M | 300M | 205M | 218M | 200M | 192M | 198M |
| Intangibles | 57M | 56M | 21M | 23M | 22M | N/A | 69M | 14M | 14M | 18M | 18M | 18M | 18M |
| Retained Earnings | 72M | 85M | 73M | 84M | 109M | 110M | 71M | 38M | -103M | -179M | -167M | -205M | -218M |
| Working Capital | 43M | 37M | 30M | 30M | 8.7M | -4.0M | -7.3M | 43M | -77M | 55M | 42M | 55M | 54M |
| Current Assets | 91M | 93M | 86M | 81M | 97M | 133M | 157M | 145M | 119M | 94M | 81M | 86M | 84M |
| Current Liabilities | 48M | 56M | 56M | 51M | 88M | 137M | 164M | 102M | 196M | 39M | 39M | 30M | 30M |
| Per Share Data | |||||||||||||
| EPS | 0.71 | 0.50 | -0.43 | 0.38 | 0.89 | 0.01 | -1.31 | -1.10 | -3.97 | -3.32 | 0.33 | -1.27 | -1.11 |
| Owner EPS | 0.47 | 0.66 | 0.29 | 0.55 | 0.11 | -0.07 | -1.31 | -0.23 | -1.47 | -1.14 | -0.38 | -0.53 | -0.19 |
| Book Value | 7.53 | 8.06 | 7.78 | 8.13 | 9.05 | 6.57 | 7.93 | 6.88 | 2.42 | -0.14 | 0.31 | 0.04 | -0.28 |
| Cash Flow/Share | 0.78 | 0.98 | 0.77 | 1.07 | 0.71 | 0.39 | -0.58 | 0.56 | -0.77 | -0.58 | 0.01 | -0.01 | -0.89 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.01 | N/A | N/A | 0.00 |
| Shares Out. | 27.0M | 27.1M | 27.1M | 27.9M | 27.9M | 41.1M | 29.2M | 29.4M | 29.4M | 30.0M | 36.4M | 34.9M | 37.5M |
| Valuation | |||||||||||||
| P/E Ratio | N/A | N/A | N/A | 35.9 | 15.8 | 1000.0 | N/A | N/A | N/A | N/A | 16.9 | N/A | -3.9 |
| P/FCF | N/A | N/A | N/A | 55.7 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | 28.7 | 31.7 | 92.6 | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | N/A | N/A | 1.7 | 1.6 | 1.5 | 1.4 | 1.7 | 3.3 | N/A | 18.0 | 180.4 | N/A |
| Price/Sales | N/A | N/A | N/A | 0.8 | 0.7 | 1.0 | 0.5 | 3.1 | 2.8 | 2.2 | 2.1 | 1.6 | 1.2 |
| FCF Yield | N/A | N/A | N/A | 1.8% | -3.5% | -7.0% | -13.6% | -2.5% | -18.1% | -16.3% | -8.9% | -5.7% | -0.6% |
| Market Cap | 0 | 0 | 0 | 380M | 392M | 411M | 320M | 351M | 290M | 238M | 203M | 241M | 162M |
| Avg. Price | 0.00 | 0.00 | 0.00 | 12.83 | 13.20 | 12.92 | 10.50 | 10.52 | 10.57 | 7.66 | 7.57 | 5.98 | 4.33 |
| Year-End Price | 0.00 | 0.00 | 0.00 | 13.65 | 14.05 | 10.00 | 10.99 | 11.97 | 9.87 | 7.94 | 5.58 | 6.90 | 4.33 |
LIFECORE BIOMEDICAL, INC. \DE\ passes 0 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 32.9%. At current prices, the estimated annualized return to fair value is -24.1%.
LIFECORE BIOMEDICAL, INC. \DE\ (LFCR) has a debt-to-equity ratio of 93.29. This indicates higher leverage, which may increase financial risk.
LIFECORE BIOMEDICAL, INC. \DE\ (LFCR) reported earnings per share (EPS) of $-1.27 in its most recent fiscal year.
LIFECORE BIOMEDICAL, INC. \DE\ (LFCR) has a return on equity (ROE) of -701.3%. A negative ROE may indicate losses or negative equity.
LIFECORE BIOMEDICAL, INC. \DE\ (LFCR) has a 5-year average gross margin of 32.9%. This indicates decent pricing power.
The Ledger Terminal provides 16 years of financial data for LIFECORE BIOMEDICAL, INC. \DE\ (LFCR), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
LIFECORE BIOMEDICAL, INC. \DE\ (LFCR) has a book value per share of $0.04, based on its most recent annual SEC filing.
No recent press releases.